NetworkNewsBreaks

FridaySep 08, 2017 12:10 pm

NetworkNewsBreaks – Achaogen, Inc. (NASDAQ: AKAO) Receives ‘Buy’ Rating at Mizuho Securities

Mizuho Securities USA LLC has initiated coverage and issued a ‘Buy’ rating and price target of $28 on shares of Achaogen, Inc.’s (NASDAQ: AKAO) stock. Achaogen has a broad pipeline of novel anti-bacterial drugs currently in development, including its lead candidate Plazomicin, which the analyst considers to be a value driver for the company. Following the positive results from the pivotal EPIC and CARE trials for treatment of complicated urinary tract infections (cUTIs) and Carbapenem Resistant Enterobacteriaceae (CRE), the company is preparing Plazomicin to file a New Drug Application (NDA) close to year-end. For more information, visit www.Achaogen.com About Achaogen…

Continue Reading

FridaySep 08, 2017 12:08 pm

NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Buy’ Rating on ViewRay, Inc. (NASDAQ: VRAY)

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $12 on shares of ViewRay, Inc.’s (NASDAQ: VRAY) stock. The company designs, manufactures and markets the MRIdian® radiation therapy system, which received CE-mark approval and 510(k) approval in February of this year. The analyst sees immense potential in the MRI-guided LINAC to disrupt current radiation oncology. The MRI-LINAC offers real-time imaging improving dosimetry and reduces the toxicity to patients, which makes for stiff competition for other companies that seem to have recently began to focus on real-time imaging. Additionally, the analyst believes that the company…

Continue Reading

FridaySep 08, 2017 12:05 pm

NetworkNewsBreaks – Mizuho Securities Initiates Coverage on Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) with ‘Buy’ Rating

Mizuho Securities USA LLC has initiated coverage and issued a ‘Buy’ rating and price target of $32 on shares of Alder BioPharmaceuticals, Inc.’s (NASDAQ: ALDR) stock. Among other highlights, the analyst noted the company’s 'de-risked' asset, Eptinezumab, slated for an upcoming phase 3 PROMISE 2 read-out anticipated during the first half of 2018. The company has previously posted positive results from its first pivotal trial, PROMISE 1, which led the analyst to expect comparable results from PROMISE 2, as the studies' designs are similar. For more information, visit www.AlderBio.com About Alder BioPharmaceuticals, Inc. Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical…

Continue Reading

FridaySep 08, 2017 12:03 pm

NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Buy’ Rating on Zogenix, Inc. (NASDAQ: ZGNX)

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $28.00 on shares of Zogenix, Inc.’s (NASDAQ: ZGNX) stock after the company hit a new 52-week high on Wednesday. The company’s lead product candidate for the treatment of seizures associated with Dravet syndrome, ZX008, was noted by the analyst as having a strong efficacy. The analyst also cited clinical data that suggests ZX008 shows a superior long-term efficacy profile over its competitors with tolerable side effects. Upcoming catalysts for the company include phase 3 read-outs in the third quarter of 2017, and either the fourth…

Continue Reading

FridaySep 08, 2017 12:01 pm

NetworkNewsBreaks – Novocure (NASDAQ: NVCR) Receives ‘Buy’ Rating from Mizuho Securities

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $25 on shares of Novocure’s (NASDAQ: NVCR) stock. Mizuho analysts noted the company’s novel treatment for cancer, Optune, has demonstrated a strong five-year overall survival benefit on cancer patients with glioblastoma (GBM), and the analyst believes it will continue to do well in the medical community. Therefore, the analyst believes Novocure will hit estimated full-year revenue of $165 million in 2017, which would represent a 95% year-over-year increase. For more information, visit www.Novocure.com About Novocure Novocure is an oncology company developing a profoundly different cancer…

Continue Reading

FridaySep 08, 2017 11:59 am

NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Buy’ Rating on Aerie Pharmaceuticals, Inc. (NASDAQ: AERI)

Mizuho Securities USA LLC has initiated coverage and issued a ‘Buy’ rating and price target of $70 on shares of Aerie Pharmaceuticals, Inc.’s (NASDAQ: AERI) stock. The analyst cites the company’s two glaucoma drugs as being well-positioned for FDA approvals, with Rhopressa anticipated for approval in the first half of 2018 and Roclatan expected to be approved in the first half of 2019. Given the strong efficacy and safety profiles of both drug candidates, the analyst believes it is likely they will both be approved. Additionally, the analyst believes that by the year 2025 the company could reach $239 million…

Continue Reading

FridaySep 08, 2017 9:14 am

NetworkNewsBreaks – Leafbuyer Technologies (LBUY) Enters Deal with Leading Dispensary Chain

Leafbuyer Technologies, Inc. (OTC: LBUY), a leading cannabis technology platform known as the premier cannabis deals network, is adding Rocky Road Remedies to its client base. Leafbuyer will provide a suite of services to Rocky Road Remedies, a leading cannabis dispensary chain with six locations in Colorado. Leafbuyer drives business to dispensaries and product clients through its online platform, Leafbuyer.com In the news release, Leafbuyer vice president of business development and co-founder Mark Breen said, “We are committed to driving business to our customer base as well as providing the best deals for the consumer in the cannabis industry.” To…

Continue Reading

ThursdaySep 07, 2017 1:09 pm

NetworkNewsBreaks – Organigram (TSX.V: OGI) (OTCQB: OGRMF) Enters into MOU for Microwave Assisted Extraction Technique Development

Organigram Holdings Inc. (TSX.V: OGI) (OTCQB: OGRMF) will jointly develop an industry leading method of microwave extraction of cannabinoid extracts from marijuana plants with the New Brunswick Innovation Research Chair in Medical Technologies (NBIRC), an initiative of the New Brunswick Innovation Fund (NBIF), it was announced Wednesday. A memorandum of understanding between Organigram Holdings Inc. and NBIRC details the project which will focus on developing a more efficient manner of extracting cannabinoids for use in extracts and edibles. The project will be led by Dr. J. R. Jocelyn Paré, holder of the NBIRC, the inventor of various Microwave-Assisted Processes forming…

Continue Reading

ThursdaySep 07, 2017 1:04 pm

NetworkNewsBreaks – Cannabics Pharmaceuticals (CNBX) Files Patent Application for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) has filed an extensive provisional patent application with the U.S. Patent & Trademark Office on a new “Method for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs.” The method, developed by Cannabics Pharmaceuticals, expands the company’s proprietary technology of personalization of cannabinoid medicine. The current invention pertains to a combined method and system for assessing the sensitivity of a variety of cannabinoid-based treatment modalities on patient-derived primary tumor biopsies as well as blood circulating tumor cells (CTC). In the news release, Dr. Moran Grinberg, Cannabics Pharmaceuticals Vice President of Research and Development,…

Continue Reading

ThursdaySep 07, 2017 12:53 pm

NetworkNewsBreaks – EVIO, Inc.’s (SGBYD) EVIO Labs Division Enters Cannabis Testing License Agreement in Colorado

EVIO, Inc. (OTCQB: SGBYD) this morning said that its cannabis testing division, EVIO Labs, has entered into an agreement with Phytatech CO, LLC to license its brand and cannabis technology in Colorado. Per the agreement, Phytatech will now operate under the EVIO Labs brand. "As we continue our mission to become the industry’s largest cannabis testing company, with operations in California, Oregon, Massachusetts, and Florida, EVIO is honored to now offer its accredited testing services to Colorado,” EVIO chief executive officer William Waldrop stated in the news release. To view the full press release, visit: http://nnw.fm/LDp24 About EVIO EVIO, Inc.…

Continue Reading